Intravenous immunoglobulin inhibits BAFF production in chronic inflammatory demyelinating polyneuropathy - A new mechanism of action?

Journal of Neuroimmunology

Volumn 256, Issue 1-2, 2013, Pages 84-90

  Bick, Sandra ^a   Tschernatsch, Marlene ^a   Karg, Anne ^a   Fuehlhuber, Verena ^a   Trenczek, Tina E ^a   Faltermeier, Kathrin ^a   Hackstein, Holger ^a   Kaps, Manfred ^a   Blaes, Franz ^a,b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Kreiskrankenhaus Gummersbach   (Germany)

Author keywords

B cell activating factor; CIDP; IVIg; Monocytes

Indexed keywords

B CELL ACTIVATING FACTOR; IMMUNOGLOBULIN;

ADULT; AGED; ARTICLE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; ANALYSIS OF VARIANCE; B-CELL ACTIVATING FACTOR; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; MONOCYTES; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; RNA, MESSENGER; TIME FACTORS;

EID: 84875369794     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.01.001     Document Type: Article

References (48)

1. Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J. Allergy Clin. Immunol. 2011, 127:315-323. (quiz 324-315).
2. Basta M., Dalakas M.C. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J. Clin. Invest. 1994, 94:1729-1735.
3. Basta M., Kirshbom P., Frank M.M., Fries L.F. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J. Clin. Invest. 1989, 84:1974-1981.
4. Bayry J., Bansal K., Kazatchkine M.D., Kaveri S.V. DC-SIGN and alpha2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:E24. (author reply E25).
5. Bayry J., Negi V.S., Kaveri S.V. Intravenous immunoglobulin therapy in rheumatic diseases. Nat. Rev. Rheumatol. 2011, 7:349-359.
6. Collart M.A., Baeuerle P., Vassalli P. Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B. Mol. Cell. Biol. 1990, 10:1498-1506.
7. Dalakas M.C. Polymyositis, dermatomyositis and inclusion-body myositis. N. Engl. J. Med. 1991, 325:1487-1498.
8. Dalakas M.C. Intravenous immune globulin therapy for neurologic diseases. Ann. Intern. Med. 1997, 126:721-730.
9. Dalakas M.C. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004, 291:2367-2375.
10. Doi M., Takeda T., Sakurai Y., Kato J., Hayashi T., Fukuda K., Takase T., Shima M. Altered immunoglobulin A and M levels associated with changes in BAFF and APRIL after administration of intravenous immunoglobulin to treat Kawasaki disease. J. Investig. Allergol. Clin. Immunol. 2010, 20:413-418.
11. Eftimov F., Winer J.B., Vermeulen M., de Haan R., van Schaik I.N. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev. 2009, (CD001797).
12. Fu L., Lin-Lee Y.C., Pham L.V., Tamayo A., Yoshimura L., Ford R.J. Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood 2006, 107:4540-4548.
13. Fuhlhuber V., Bick S., Kirsten A., Hahn A., Gerriets T., Tschernatsch M., Kaps M., Preissner K.T., Blaes F., Altenkamper S. Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome. J. Neuroimmunol. 2009, 210:87-91.
14. Groom J., Kalled S.L., Cutler A.H., Olson C., Woodcock S.A., Schneider P., Tschopp J., Cachero T.G., Batten M., Wheway J., Mauri D., Cavill D., Gordon T.P., Mackay C.R., Mackay F. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J. Clin. Invest. 2002, 109:59-68.
15. Hedegaard C.J., Sellebjerg F., Krakauer M., Hesse D., Bendtzen K., Nielsen C.H. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production. Mult. Scler. 2010, 17:567-577.
16. Hughes R.A. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial. Expert. Rev. Neurother. 2009, 9:789-795.
17. Hughes R., Bensa S., Willison H., Van den Bergh P., Comi G., Illa I., Nobile-Orazio E., van Doorn P., Dalakas M., Bojar M., Swan A. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 2001, 50:195-201.
18. Hughes R.A., Donofrio P., Bril V., Dalakas M.C., Deng C., Hanna K., Hartung H.P., Latov N., Merkies I.S., van Doorn P.A. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008, 7:136-144.
19. Ichiyama T., Ueno Y., Hasegawa M., Niimi A., Matsubara T., Furukawa S. Intravenous immunoglobulin inhibits NF-kappaB activation and affects Fcgamma receptor expression in monocytes/macrophages. Naunyn Schmiedebergs Arch. Pharmacol. 2004, 369:428-433.
20. Kaveri S., Prasad N., Vassilev T., Hurez V., Pashov A., Lacroix-Desmazes S., Kazatchkine M. Modulation of autoimmune responses by intravenous immunoglobulin (IVIg). Mult. Scler. 1997, 3:121-128.
21. Kerur N., Veettil M.V., Sharma-Walia N., Sadagopan S., Bottero V., Paul A.G., Chandran B. Characterization of entry and infection of monocytic THP-1 cells by Kaposi's sarcoma associated herpesvirus (KSHV): role of heparan sulfate, DC-SIGN, integrins and signaling. Virology 2010, 406:103-116.
22. Kieseier B.C., Meyer Zu Horste G., Lehmann H.C., Gold R., Hartung H.P. Intravenous immunoglobulins in the treatment of immune neuropathies. Curr. Opin. Neurol. 2008, 21:555-562.
23. Krause I., Blank M., Shoenfeld Y. Anti-DNA and antiphospholipid antibodies in IVIG preparations: in vivo study in naive mice. J. Clin. Immunol. 1998, 18:52-60.
24. Krumbholz M., Faber H., Steinmeyer F., Hoffmann L.A., Kumpfel T., Pellkofer H., Derfuss T., Ionescu C., Starck M., Hafner C., Hohlfeld R., Meinl E. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 2008, 131:1455-1463.
25. Krystufkova O., Vallerskog T., Helmers S.B., Mann H., Putova I., Belacek J., Malmstrom V., Trollmo C., Vencovsky J., Lundberg I.E. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann. Rheum. Dis. 2009, 68:836-843.
26. Le Pottier L., Bendaoud B., Dueymes M., Daridon C., Youinou P., Shoenfeld Y., Pers J.O. BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer. J. Clin. Immunol. 2007, 27:257-265.
27. Lehmann H.C., Hartung H.P. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies. J. Neuroimmunol. 2010, 231:61-69.
28. Lemm G. Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy. Neurology 2002, 59:S28-S32.
29. Li X., Su K., Ji C., Szalai A.J., Wu J., Zhang Y., Zhou T., Kimberly R.P., Edberg J.C. Immune opsonins modulate BLyS/BAFF release in a receptor-specific fashion. J. Immunol. 2008, 181:1012-1018.
30. Libermann T.A., Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol. Cell. Biol. 1990, 10:2327-2334.
31. Mackay F., Leung H. The role of the BAFF/APRIL system on T cell function. Semin. Immunol. 2006, 18:284-289.
32. Mackay F., Schneider P. Cracking the BAFF code. Nat. Rev. Immunol. 2009, 9:491-502.
33. Moore P.A., Belvedere O., Orr A., Pieri K., LaFleur D.W., Feng P., Soppet D., Charters M., Gentz R., Parmelee D., Li Y., Galperina O., Giri J., Roschke V., Nardelli B., Carrell J., Sosnovtseva S., Greenfield W., Ruben S.M., Olsen H.S., Fikes J., Hilbert D.M. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999, 285:260-263.
34. Mukhopadhyay A., Ni J., Zhai Y., Yu G.L., Aggarwal B.B. Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase. J. Biol. Chem. 1999, 274:15978-15981.
35. Nardelli B., Belvedere O., Roschke V., Moore P.A., Olsen H.S., Migone T.S., Sosnovtseva S., Carrell J.A., Feng P., Giri J.G., Hilbert D.M. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001, 97:198-204.
36. Nimmerjahn F., Ravetch J.V. Fcgamma receptors as regulators of intravenous immunoglobulin. Nat. Rev. Immunol. 2008, 8:34-47.
37. Nimmerjahn F., Ravetch J.V. Antibody-mediated modulation of immune responses. Immunol. Rev. 2010, 236:265-275.
38. Nobile-Orazio E., Gallia F., Tuccillo F., Terenghi F. Chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: treatment update. Curr. Opin. Neurol. 2010, 23:519-523.
39. Pers J.O., Daridon C., Devauchelle V., Jousse S., Saraux A., Jamin C., Youinou P. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann. N. Y. Acad. Sci. 2005, 1050:34-39.
40. Samuelsson A., Towers T.L., Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001, 291:484-486.
41. Schneider P., MacKay F., Steiner V., Hofmann K., Bodmer J.L., Holler N., Ambrose C., Lawton P., Bixler S., Acha-Orbea H., Valmori D., Romero P., Werner-Favre C., Zubler R.H., Browning J.L., Tschopp J. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J. Exp. Med. 1999, 189:1747-1756.
42. Shu H.B., Hu W.H., Johnson H. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J. Leukoc. Biol. 1999, 65:680-683.
43. Thien M., Phan T.G., Gardam S., Amesbury M., Basten A., Mackay F., Brink R. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004, 20:785-798.
44. Tschernatsch M., Blaes F. Clinical and diagnostic findings in chronic immune-mediated neuropathies. Klin. Neurophysiol. 2010, 41:224-235.
45. Vincent A., Palace J., Hilton-Jones D. Myasthenia gravis. Lancet 2001, 357:2122-2128.
46. Yan W.X., Taylor J., Andrias-Kauba S., Pollard J.D. Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann. Neurol. 2000, 47:765-775.
47. Yoshimoto K., Takahashi Y., Ogasawara M., Setoyama Y., Suzuki K., Tsuzaka K., Abe T., Takeuchi T. Aberrant expression of BAFF in T cells of systemic lupus erythematosus, which is recapitulated by a human T cell line, Loucy. Int. Immunol. 2006, 18:1189-1196.
48. Zhang J., Roschke V., Baker K.P., Wang Z., Alarcon G.S., Fessler B.J., Bastian H., Kimberly R.P., Zhou T. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol. 2001, 166, 6-166, 10.